TRANS-RESVERATROL ANTI-AGING EFFECT-YEAST TO HUMAN TRIAL: A REVIEW

PDF

Published: 2021-12-23

Page: 619-628


MRITUNJAY KUMAR SINGH *

Invertis University., NH-24, Bareilly-243123 UP, India.

PANKAJ KUMAR RAI

Department of Biotechnology, Invertis University, NH-24, Bareilly-243123 UP, India.

RAVI DEVAL

Rohilkhand Laboratory and Research Centre, B-4, Parsakhera Industrial Area-243502 UP, India.

*Author to whom correspondence should be addressed.


Abstract

Tras-resveratrol gained popularity since it was reported to be associated with its antiaging effect. Many sources are reported to have resveratrol. Peanut (Arachis hypogaea) is also one of them that produces trans-resveratrol, a compound with various biological properties like antioxidant, anticancer, and anti-inflammatory effects as well. In many studies, trans-resveratrol was detected in the roots, leaves, and stems and purple seed coats of peanuts cultivated in a sterile environment. Generally, peanut produces not much amount of resveratrol but when the peanut plant faces biotic stress, it produces enough amount of trans-resveratrol. This resveratrol may be detected by reverse-phase HPLC. The various experiments conducted on the culture of Saccharomyces cerevisiae showed a positive result as far as the antiaging effect is concerned. The promising results obtained during experiments promoted various pharmaceutical companies to synthesize and sell in the form of plant extract. Slowly, trans-resveratrol has gained good market value as an antiaging product. It has been a long journey since 2000 when the very first time trans-resveratrol came into existence as an antiaging compound and yeast was the biological model. Since then various model organisms were selected to finally reach human trials. But still, the exact pathway is not clear, therefore, it is imperative to study different model organisms. Although in recent past, many human trials have been reported and the result was also astonishing. In the current scenario, various human trials are going on but no antiaging project on humans has been reported. This review encourages more researches to see the antiaging effects of trans-resveratrol.

Keywords: DNA methylation, sirt, biological age, NAD, histone deacetylase, chronological age


How to Cite

SINGH, M. K., RAI, P. K., & DEVAL, R. (2021). TRANS-RESVERATROL ANTI-AGING EFFECT-YEAST TO HUMAN TRIAL: A REVIEW. UTTAR PRADESH JOURNAL OF ZOOLOGY, 42(24), 619–628. Retrieved from https://mbimph.com/index.php/UPJOZ/article/view/2757

Downloads

Download data is not yet available.

References

Woodroof JG, Peanuts: Production, processing, products. The AVI Publishing Company, Inc. Westport, CT. 1973;330.

Sanders TH, McMichael RW. Occurrence of Resveratrol in edible peanuts. Peanut Institute; 1998.

Godson O. Osuji, Paul Johnson et. al. Horticultural Production of Ultra High Resveratrol Peanut.Agricultural Sciences. 2017;(8)10.

Manimaran M, Sivakumari K, Ashok K, Rajesh S PG. Evaluation of the in vitro anti-microbial effect of resveratrol on human pathogens. International Journal of Zoology Studies. 2017 ;( 2)124-127.

Kennedy BK, Austriaco NR Jr, Zhang J, Guarente L. Mutation in the silencing gene SIR4 can delay aging in S cerevisiae. Cell. 1995;80:485–496.

Pacholec M, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem. 2010; 285:8340–8351. [PubMed: 20061378]

Sinclair DA, Guarente L. Extrachromosomal rDNA circles — a cause of aging in yeast. Cell. 1997;91:1033–1042. The first study to show that replicative lifespan is mediated by the accumulation of ERCs.

Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 1999; 13:2570–2580.

Stumpferl SW, et al. Natural genetic variation in yeast longevity. Genome Res. 2012; 22:1963– 1973.

Landry J, et al. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Natl Acad Sci USA. 2000; 97:5807–5811.

Silvie Timmers, Johan Auwerx, Patrick Schrauwen, The journey of resveratrol from yeast to human, Aging. 2012;4(3):146-58.

John L. Ingham.3,5,4-trihydroxystilbene as a phytoalexin from groundnuts (Arachis hypogaea).Phytochemistry. 1976;15:1791-1793.

Alison Abbott. In focus. Nature. 2019;573.

Yasmeen Salameh, Yosra Bejaoui and Nady El Hajj. DNA methylation biomarkers in aging and age-related diseases. Frontiers in Genetics. 2020;(11)171.

Almeida L, Vaz‐da‐Silva M et.at. Pharmacokinetic and safety profile of transresveratrol in a rising multiple‐dose study in healthy volunteers. Mol Nutr Food Res. 2009;53(Suppl 1): S7‐15.

Boocock DJ, Patel KR et al. Quantitation of trans‐resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;848: 182‐187.

Brown VA, Patel KR et.al. Repeat dose study of the cancer chemo preventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin like growth factor axis. Cancer Res. 2010;70: 9003‐9011.

Burkon A and Somoza V. Quantification of free and protein bound trans‐resveratrol metabolites and identification of transresveratrol‐ C/O‐conjugated diglucuronides-two novel resveratrol metabolites in human plasma. Mol Nutr Food Res. 2008;52:549‐557.

la Porte C, Voduc N et al. Steady‐State pharmacokinetics and tolerability of trans‐resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet. 2010;49: 449‐454.

López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194–1217.

Kaeberlein, M. et al. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science. 2005;310:1193–1196 ().

Longo VD, Shadel GS, Kaeberlein M, Kennedy B. Replicative and chronological aging in Saccharomyces cerevisiae. Cell Metab. 2012;16:18–31.

Smith AM, et al. Quantitative phenotyping via deep barcode sequencing. Genome Res. 2009;19:1836–1842.

Ruofan Yu, Xiaohua, Luyang, Jun-yi Zhu et. al. Inactivating histone deacetylase HDA promotes longevity by mobilizing trehalose metabolism. Nature Communications. 2021;12:1981.

Harper S. Economics and social implications of aging societies. Science. 2014;346:587-591.

Goldman DP, Cutler D, Rowe JW et. al. Substantial health and economic returns from delayed aging may warrant A new focus for medical research. Health Affairs. 2013; 32:1698-1705.

Gladyshev VN. Aging: progressive decline in fitness due to the rising deleteriome adjusted by genetic, environment, and stochastic processes. Aging Cell. 2016;15:594-602.

Kirkwood TB. Understanding the odd science aging. Cell. 2005;120:437-447.

Kennedy BK, Berger SL, Brunet A et. al. Geroscience: Linking Aging to Chronic Disease. Cell. 2014;159:709-713.

Lopez-OtinC, Blasco MA, Patridge L, Serrano M et.al. The hallmarks of aging. Cell. 2013;153: 1194-1217.

Campisi J, Kapahi P, Lithgow GJ, Melov S, et.al. From discoveries in aging research to therapeutics for healthy aging. Nature. 2019;571:183-192.

Kaeberlein M, Rabinovitch PS, Martin GM et.al. Healthy aging: the ultimate preventive medicine. Science. 2015;350:1191-1193.

Moskalev A, Chernyagina E, Tsvetkov A, Fedintsev A et.al. Developing criteria for evaluation of gero-protectors as a key stage toward translation to the clinic. 2016;15:407-415.

Justice J, Miller JD, Newman JC, Hashmi SK, et.al.Frameworks for Proof-of-Concept clinical trials of intervenstions that target fundamental aging processes.The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2016;71:1415-1423.

Justice JN, Ferrucci L, Newman AB, et.al. A framework for selection of blood-based biomarkers for gero-scienceguided clinical trials:report from the TAME biomarkers work group. GeroScience. 2018;40:1419-436.

Moskalev A, Chernyagina E, Tsvetkov A, Fedintsev A, et al. Developing criteria for evaluation of geroprot-ectors as a key stage toward translation to the clinic. Aging Cell. 2016;15:407-415.

Zhavoronkov A, et al. Classifying aging as a disease in the context of ICD-11. Front Genet. 2015;4(6):326.

Blagosklonny MV. Disease or not, aging is easily treatable. Aging (Albany NY). 2018. 17;10(11):3067-3078.

Editorial. Opening the door to treating ageing as a disease. Lancet Diabetes Endocrinol. 2018. t;6(8):587.

Lopex-Otin C, et al. The hallmarks of aging. Cell. 2013;153(6):1194-1217.

Schultz MB, et al. Why NAD+ Declines during Aging: It’s Destroyed. Cell Metab. 2016;23(6): 965–966.

Zhu XH, et al. In vivo NAD assay revels the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc. Natl. Acad. Sci. 2015; 112:2876–2881.

Suave AA. NAD+ and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther. 2008;324(3):883-93.

Lee CF, et al. Targeting NAD+ Metabolism as Interventions for Mitochondrial Disease. Sci Rep. 2019;9(1):3073.

Camacho-Pereira J, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23(6):1127-1139.

Longo VD, et al. Interventions to slow aging in humans: are we ready? Aging Cell. 14(4): 497-510.

Revollo JR, et al. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyl-transferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279:50754–50763.

Mills KF, et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metab. 2016;24:795–806.

Hallschmid M, et al. Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans. Diabetes. 2009; 58:637–640.

Friebe D, et al. Leucocytes are a major source of circulating nicotinamide phosphoribosyl-transferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia. 2011;54:1200–1211.